Literature DB >> 9270988

Chronic exertional dyspnea and respiratory muscle function in patients with chronic obstructive pulmonary disease.

K Ferrari1, P Goti, G Misuri, M Amendola, E Rosi, M Grazzini, I Iandelli, R Duranti, G Scano.   

Abstract

The symptom of breathlessness is an important outcome measure in the management of patients with chronic obstructive pulmonary disease (COPD). Clinical ratings of dyspnea and routine lung function are weakly related to each other. However, in the clinical setting breathlessness in COPD is encountered under conditions of increased respiratory effort, impeded respiratory muscle action, or functional weakness. Thus, the present study was carried out to determine whether and to what extent clinical ratings of dyspnea and respiratory muscle dysfunction relate to each other. In 21 patients with COPD two methods were used to rate dyspnea: a modified Medical Research Council Scale (MRC) and the Baseline Dyspnea Index (BDI), which is a multidimensional instrument for measuring dyspnea based on three components: magnitude of task, magnitude of effort, and functional impairment. A baseline focal score was obtained as the sum of the three components. Measures were: pulmonary volumes; arterial blood gases; maximal voluntary ventilation (MVV); maximal inspiratory and expiratory pressures (MIP and MEP, respectively); and breathing patterns ventilation (VE), tidal volume (VT), and respiratory frequency (Rf). In 15 patients pleural pressure was also measured during both quiet breathing (Pplsw) and maximal inspiratory sniff maneuver at FRC (Pplsn). BDI and MRC ratings related to each other and showed comparable weak associations with standard parameters (FEV1, PaCO2, VT), MIP, and MEP. In contrast, MVV closely and similarly related to both ratings. Pplsw (%Pplsn), a measure of respiratory effort, and Pplsw (%Pplsn)/VT(%VC), an index of neuroventilatory dissociation, related significantly to both the BDI (r2 = -0.77 and r2 = -0.75, respectively) and the MRC (r2 = 0.81 and r2 = 0.74, respectively). Using MVV, Pplsw (%Pplsn), and Pplsw (%Pplsn)/VT(%VC) in a stepwise multiple regression as independent variables with BDI rating as dependent variable, MVV explained an additional 14.5% of the variance of the BDI over the 67.8% predicted by Pplsw (%Pplsn). Our results demonstrate that the level of chronic exertional dyspnea in COPD increases as the ventilatory muscle derangement increases. The level of the relationships among dyspnea ratings and MVV and respiratory effort helps to explain some of the mechanisms of chronic dyspnea of COPD. These measures should be considered for therapeutic intervention to reduce dyspnea.

Entities:  

Mesh:

Year:  1997        PMID: 9270988     DOI: 10.1007/pl00007577

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  7 in total

1.  Expiratory muscle endurance in chronic obstructive pulmonary disease.

Authors:  A Ramírez-Sarmiento; M Orozco-Levi; E Barreiro; R Méndez; A Ferrer; J Broquetas; J Gea
Journal:  Thorax       Date:  2002-02       Impact factor: 9.139

Review 2.  Clinical management of chronic obstructive pulmonary disease patients with muscle dysfunction.

Authors:  Joaquim Gea; Carme Casadevall; Sergi Pascual; Mauricio Orozco-Levi; Esther Barreiro
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

3.  Abdominal muscle and quadriceps strength in chronic obstructive pulmonary disease.

Authors:  W D-C Man; N S Hopkinson; F Harraf; D Nikoletou; M I Polkey; J Moxham
Journal:  Thorax       Date:  2005-05-27       Impact factor: 9.139

Review 4.  Nutritional status and muscle dysfunction in chronic respiratory diseases: stable phase versus acute exacerbations.

Authors:  Joaquim Gea; Antoni Sancho-Muñoz; Roberto Chalela
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

5.  Serum Creatinine to Cystatin C Ratio is an Effective Indicator for Muscle Strength Decline in Men with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Authors:  Dan Huang; Canhui Xie; Chaoqun Sun; Min Chen; Lian Li; Huajuan Yi; Jinyu Liao; Xuanna Zhao; Xiaoping Shen; Donglan He; Dongming Li; Dong Wu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-04-08

6.  Dyspnea assessment and adverse events during sputum induction in COPD.

Authors:  Demosthenes Makris; Nikolaos Tzanakis; Joanna Moschandreas; Nikolaos M Siafakas
Journal:  BMC Pulm Med       Date:  2006-06-29       Impact factor: 3.317

7.  Modified Medical Research Council scale vs Baseline Dyspnea Index to evaluate dyspnea in chronic obstructive pulmonary disease.

Authors:  Thierry Perez; Pierre Régis Burgel; Jean-Louis Paillasseur; Denis Caillaud; Gaetan Deslée; Pascal Chanez; Nicolas Roche
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-08-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.